Challenges of safety evaluation.

Area of Science:

• Pharmacology
• Toxicology
• Regulatory Science

Background:

• Marketing authorisation applications for medicinal products require specific documentation per Directive 2001/83/EC.
• Traditional herbal medicinal products (THMPs) have specific documentation requirements outlined in Article 16c of Directive 2001/83/EC.
• Guidance for THMP applications, including the use of the CTD format and non-clinical safety data, is provided by the Committee on Herbal Medicinal Products (HMPC).

Purpose of the Study:

• To elucidate the non-clinical safety evaluation requirements for traditional herbal medicinal products (THMPs).
• To provide guidance on handling incomplete non-clinical safety data for THMPs.
• To detail the performance and interpretation of mutagenicity studies for THMP applications.

Main Methods:

• Review of Directive 2001/83/EC and relevant HMPC guidelines (EMA/HMPC/71049/2007 Rev. 1, EMEA/HMPC/32116/2005).
• Analysis of requirements for bibliographic safety data review within the 'Non-clinical Overview'.
• Focus on the performance and interpretation of mutagenicity studies for THMPs.

Main Results:

• A bibliographic review of safety data, expert reports, and potentially additional data are required for THMP applications.
• Incomplete non-clinical safety data for THMPs with a long tradition of use can be addressed using established guidelines.
• Specific methodologies for conducting and interpreting mutagenicity studies are crucial for non-clinical safety assessment.

Conclusions:

• Understanding and meeting the non-clinical safety data requirements is essential for successful THMP marketing authorisation.
• The HMPC guidelines offer a framework for presenting safety data, even when historical data is incomplete.
• Standardized approaches to mutagenicity testing and interpretation are vital for ensuring the safety of traditional herbal medicinal products.